Figure 1
(a) The trends of blood hemoglobin levels in the olaparib group are shown. There were 30 cases of initial interruption of treatment due to anemia after the start of treatment. Treatment was interrupted when the hemoglobin level fell below 8 mg/dL. A total of 22/30 (73.3%) patients was interrupted within 4–12 weeks of treatment. (b) The trends of blood platelet levels in the niraparib group are shown. There were 16 cases of initial interruption of treatment due to thrombocytopenia after the start of treatment. Treatment was interrupted when the platelet level fell below 100,000/µL. A total of 15/16 (73.3%) patients was interrupted within 8 weeks of treatment.
